Background/Aims: The oncogenic role of linc00152 in pan-cancer is unclear. Methods: In this study, RNA-Seq of 33 breast specimens was performed, and the expression of linc00152 was validated by qPCR using 50 paired breast cancer tissues and adjacent normal tissues. This result combined with the expression of linc00152 in pan-cancer was revalidated by Gene Expression Omnibus and The Cancer Genome Atlas data. Next, the oncogenic roles of linc00152 in view of prognosis, chemoresistance, genomic and epigenetic regulation, including DNA methylation and histone modification, potential biological function enrichment, and basic molecular function in pan-cancer, were also evaluated in vitro and in vivo. Results: Linc00152 is upregulated in pan-cancer, especially in progressive cancer, and the high expression of linc00152 may lead to a worse prognosis and chemoresistance in pan-cancer patients. Amplification, DNA hypomethylation, promoter-like lncRNA characteristics and super-enhancer regulation are the drivers that lead to the upregulation of linc00152 in pancancer. Meanwhile, linc00152 was involved in cancer-related pathways, infection and immune response-associated pathways by enriched analysis using TCGA data. Finally, linc00152 was confirmed to promote the proliferation, migration and invasion in MDA-MB-231, SGC-7901 and 786-O. Moreover, RIP and RNA pull-down assays indicated that linc00152 can bind to EZH2 directly. Conclusion: All of the results indicated that linc00152 acted as an oncogenic propellant from various perspectives, and it may be an effective therapy target in pan-cancer.
Guilt-by-association analysis
Data from the TCGA was evaluated to compute a pairwise Pearson correlation between the expression of linc00152 and all of the genes. Only associated genes with an absolute r ≥ 0.6 and a significant correlation (P < 0.05) were retained. Gene ontology term enrichment and KEGG pathway analysis were analyzed with these genes using DAVID, as previously described [19, 20] .
Cell culture experiments MDA-MB-231 cells were cultured in DMEM (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum and 100 units/ml penicillin/streptomycin at 37°C in an atmosphere without CO 2 . SGC-7901 and 786-O cells were cultured in a 1640 medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum and 100 units/ml penicillin/streptomycin at 37°C in an atmosphere containing 5% CO 2 . All of the cell lines were obtained from the Chinese Type Culture Collection, Chinese Academy of Sciences. Cells were used during their logarithmic growth phase.
Linc00152 knockdown and qRT-PCR
To silence linc00152 expression, an shRNA sequence targeting LINC00152 was produced and cloned into the lentivirus vector. Two shRNAs were designed to target linc00152 (shR_1: 5′-TGTGGACTCTGAGGCCTCTGCATTT -3′ and shR_2: 5′-TCTATGTGTCTTAATCCCTTGTCC T-3′). An shRNA without sequence homology to human genes was used as the negative control. Recombinant lentivirus was generated from 293T cells, and the stable cells infected with LINC00152 shRNA were selected by puromycin. The knockdown efficiency of the LINC00152 was examined by qRT-PCR. qRT-PCR was performed using the SYBR-Green method, and the specific sequences of the primers used were 5′-CTGGATGGTCGCTGCTTTTT-3′ (forward) and 5′-GATCTGAAGACAGGCACGGG-3′ (reverse) for linc00152; and 5′-GCACCGTCAAGGCTG AGAAC-3′ (forward) and 5′-GGATCTCGCTCCTGGAAGATG-3′ (reverse) for GAPDH. Quantitative normalization of linc00152 cDNA was performed for each sample using GAPDH expression as an internal control. The relative levels of linc00152 vs. GAPDH were determined by the comparative CT (2 −ΔΔCT ) method.
Cell proliferation, migration and invasion assay
Cell proliferation assays were performed using the Cell Counting Kit-8 according to the manufacturer's instructions (Beyotime, Shanghai, China). Briefly, 2 × 10 3 cells were seeded in a 96-well plate. Cell proliferation was assessed at 24, 48, and 72 h. After the addition of 20 μl of WST-1 reagent per well, the cultures were incubated for 2 h, and the absorbance was measured at 490 nm using a microplate reader (BioTek, VT, United States). For migration assay, MDA-MB-231 cells were seeded into the upper chambers of transwell culture plates, each with an 8-μm pore membrane insert (Corning, Shanghai, China). L-15 medium supplemented with 20% FBS was placed in the lower chambers. For invasion assay, the transwell chambers were firstly coated with matrigel solution. Then, MDA-MB-231 cells were seeded into the upper chambers of the transwells and L-15 medium with 20% FBS (600 μL) was added to the lower chambers. After incubation for 48 h in migration or invasion assays, cells that had penetrated through to the lower surface of the membrane were fixed with 4% paraformaldehyde for 30 min, stained with crystal violet for 30 min, and counted the cells in six randomly chosen fields.
Flow cytometry
An Annexin-PE Apoptosis detection kit (BD Biosciences, San Jose, CA) was used to examine cell apoptosis according to the manufacturer's instructions. Briefly, cells were washed twice in cold PBS, harvested and resuspended in 1 × binding buffer. Next, 100 μl of the cell solution (1 × 10 5 cells) was transferred into a 5-ml culture tube, and 5 μl of annexin V-PE and 5 μl of 7-AAD were added. The cells were gently vortexed and incubated for 15 min at RT (25°C) in the dark. Next, 400 μl of 1 × binding buffer was added to each tube, and apoptosis analysis was performed on a FACScan instrument (Becton Dickinson, Mountain View, CA, USA).
Xenografts in mice
Stable knockdown cells or control cells were subcutaneously injected into two groups of athymic female BALB/c mice (5 weeks old). After three weeks injection, all mice were sacrificed and the tumors were isolated and weighed. The study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocols were finally approved by the committee on animal experimentation of Harbin Medical University. 
Statistical analyses
The expression of linc00152 was dichotomized using the median expression as the cut-off to define "high value" at or above the median versus "low value" below the median. Overall survival was calculated as the time from surgery until the occurrence of death. Any event-free survival was calculated as the time from surgery until the occurrence of any relapse or death. Metastasis-free survival was calculated as the time from surgery until the occurrence of distant relapse. The differences between the groups in our in vitro experiments were analyzed using Student's t-test. Spearman correlation coefficients were calculated for correlation analysis. All of the experiments were performed in triplicate, and SPSS 16.0 software (SPSS, Chicago, IL) was used for statistical analysis. All of the statistical tests were two-sided, and P < 0.05 was considered to be statistically significant.
Results

Linc00152 is upregulated in breast cancer
Thirty-three specimens, including breast cancer tissue (N=15) and adjacent normal tissue (N=15), as well as breast tissue from non-cancer patients (N=3), were obtained and subjected to RNA-Seq analysis performed by our cohort. Linc00152 showed higher expression in cancer tissues than in non-cancer tissues (Fig. 1A) . Next, this result was validated by TCGA and GEO data. Linc00152 showed high expression in breast cancer tissues in 837 patients from TCGA and 10 datasets (GSE20685, GSE12763, GSE21422, GSE10810, GSE7904, GSE29431, GSE42568, GSE10780, GSE48390 and GSE21653) containing 1, 215 patients from GEO ( S1 ). To further confirm the linc00152 expression model, 50 paired breast cancer and non-cancer tissues were applied to revalidate the result in our cohort. As expected, linc00152 showed higher expression in cancer tissues than in its non-cancer counterpart significantly (Fig. 1C) . 
Linc00152 is closely related to cancer with progressive characteristics
For breast cancer, linc00152 was expressed very highly in patients with progressive triple-negative and HER-2 subtypes in TCGA ( Fig. 2A) . Meanwhile, its expression was also high in patients with ER-negative, PR-negative and HER-2-positive cancers than in their counterparts (Fig. 2B , 2C and 2D). Next, linc00152 was expressed at a lower level in breast cancer with the luminal A subtype but showed higher expression in other progressive subtypes in our 33 RNA-seq specimens (Fig. 2E ). Breast cancer cell lines were also investigated from CCLE (http://software.broadinstitute.org/software/cprg/?q=node/11) to validate this result. As expected, linc00152 showed higher expression in triple-negative or HER-2 overexpression cell lines than in luminal cancer cell lines (Fig. 2F) . Additionally, other cancers were examined to investigate the linc00152 expression model. The expression levels of linc00152 were higher in bladder carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, thyroid carcinoma and endometrioid carcinoma than in their non-cancer counterparts in TCGA (Fig. 2G) . Moreover, high-grade and high TNM Cellular
stage were also accompanied with the high expression of linc00152 in bladder carcinoma and renal clear cell carcinoma (Fig. 2H and 2I ).
High expression of linc00152 leads to a worse prognosis in pan-cancer patients
Next, the relationship between linc00152 expression and prognosis in pan-cancer was investigated via TCGA and GEO data. High expression of linc00152 indicates a worse overall survival in patients with renal clear cell carcinoma or lung adenocarcinoma or lower grade glioma (P<0.001; P=0.033; P<0.001, respectively) (Fig. 3A, 3B and 3C) . Meanwhile, high expression of linc00152 in patients with breast cancer also indicates a trend of worse overall survival without significance (data not supplied). Thus, all datasets from GEO containing the data of linc00152 expression and complete follow-up information were collected to perform the survival analysis. As expected, high expression of linc00152 in breast cancer patients showed a worse any event-free survival (AES) and metastasis-free survival (MFS) in 12 datasets with 5, 802 patients in GEO (P<0.001; P<0.01, respectively) (Fig. 3D, 3E and see online suppl. material, Table S1 ). Moreover, meta-analyses were also performed to investigate the relationship between linc00152 expression and any event-free survival and metastasis-free survival. Patients with high expression of linc00152 have a higher risk of AES and MFS than those with low expression of linc00152 (P<0.001, HR=1.28; P<0.001, HR=1.36, respectively) ( Fig. 3F and 3G ).
Linc00152 induces chemoresistance in pan-cancer
The relationship between linc00152 and chemoresistance was also investigated subsequently. GSE16089 and GSE16446 were selected to meet the study need. In the GSE16089 dataset, seven cell lines representative of different types of cancers, including (Fig. 4A, 4B and 4C ). Linc00152 is one of the upregulated genes of the 551 overlapping genes in these cell line cohorts ( Fig. 4D and 4E ). In the GSE16446 dataset, anthracycline-resistance genes were examined by microarray analysis of 149 breast cancer patients with neoadjuvant chemotherapy. Linc00152 was upregulated in patients without a pathological complete response (data not supplied). In addition to these results, a previous study identified that the linc00152/miR-193a-3p/erbB-4/AKT signaling axis confers oxaliplatin resistance in colon cancer [21] . Overall, linc00152 may lead to chemoresistance in pan-cancer.
Regulation of Linc00152 expression
The relationship between copy number variations and the upregulation of linc00152 was performed in breast cancer by TCGA data. Obvious amplification was observed in breast cancer samples with high linc00152 expression (Fig. 5A) . Moreover, the result can be obtained in pan-cancer (Fig. 5B) . Linc00152 expression was inversely correlated with the DNA methylation of the linc00152 locus in breast cancer in TCGA (Fig. 5C) . A previous study showed that the promoter region of linc00152 was hypomethylated in hepatic carcinoma tissues than in para-cancer tissues via bisulfite sequencing polymerase chain reaction [22] (D) Linc00152 was hypomethylated in hepatic carcinoma tissues compared with para-cancer tissues via bisulfite sequencing polymerase chain reaction [22] . (E) DNA methylation in the linc00152 locus in pan-cancer tissues and that in normal tissues in 450K data from TCGA. The blue columns indicate the β value in cancer tissues, and the red columns represent that in normal tissues. * P<0.05, ** P<0.01. (Fig. 5D ). For the upregulation of linc00152 in pan-cancer, we hypothesized that the DNA methylation level would be lower in the linc00152 locus in cancer tissues than that in normal tissues. Thus, the 450K data from TCGA was downloaded and analyzed. The results showed that low linc00152 locus methylation was observed in 17 types of cancers than in their noncancer counterparts (Fig. 5E ).
Linc00152 and promoter/super-enhancer regulation
Next, the relationship between linc00152 expression and histone modification was analyzed using ENCODE data. Based on the ratio of H3K4me3/H3K4me1, lncRNA can be divided into promoter-like lncRNA and enhancer-like lncRNA groups [23] . Linc00152 with the ratio of H3K4me3/H3K4me1>1.2 at the transcription start site is regarded as a Cellular Physiology and Biochemistry
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closely related to the binding of transcription factors and enrichment of H3K27ac [24] . The relationship between linc00152 upregulation and super-enhancer regulation was next investigated using the SEA database [25] . The results indicated that linc00152 is localized in the super-enhancer region in six cancer cell lines (Fig. 6B) . The distance of 50 to 500 kb to the target gene transcription start sites is observed in 59 super-enhancers ( Fig. 6C  and 6D ). SE50407, a super-enhancer that regulates the expression of linc00152, was bound by several oncogenic transcription factors, including FOS, ZEB-1, and MAX (Fig. 6E) . Thus, Linc00152 as a promoter-like lncRNA and regulated by a super-enhancer may explain its overexpression in pan-cancer.
Potential biological functions of linc00152
To explore the possible functions of linc00152, guilt-by-association analyses were applied using TCGA data, as described in the Methods section. Gene ontology term enrichment (GO) and KEGG pathway analysis were performed for the potential functions and pathways that linc00152 may be involved in using enriched genes. The main functions of linc00152 were leukocyte migration, extracellular matrix organization, immune response, and cell adhesion, and the main pathways that linc00152 were involved in included the Staphylococcus aureus infection, phagosome, focal adhesion and PI3K-Akt signaling pathways (Fig. 7A, 7B and see online suppl. material, Table S2 ). The representative co-expressed genes of linc00152 and genes that participate in PI3K-Akt signaling pathway were examined subsequently ( Fig. 7C  and 7D ). The proteins that were expressed positively or negatively with linc00152 were explored in TCGA RPPA data. Bladder cancer, brain lower grade glioma and glioblastoma multiforme contained such data, and the results indicated that PAI-1 was the overlapping protein in three cohorts ( Fig. 7E and see online suppl. material, Table S3 ). Moreover, PAI-1 was positively expressed with linc00152 in glioblastoma multiforme (P<0.001) (Fig. 7F) . Additionally, previous studies have indicated that PAI-1 was involved in breast cancer, ovarian cancer, prostate cancer, colorectal cancer, and cervical cancer [26] [27] [28] [29] [30] . Thus, linc00152 may function as an oncogene in pan-cancer.
Linc00152 promotes tumor cell proliferation, migration and invasion
To elucidate the potential biological functions of linc00152 in tumorigenesis, a breast cancer cell line (MDA-MB-231), gastric cancer cell line (SGC-7901) and renal cancer cell line (786-O) were selected for functional study. Stable knockdown of linc00152 was performed using purified lentivirus with two different shRNAs (see online suppl. material, Fig. S2 ). The CCK-8 assay and clonogenic assay indicated that the knockdown of linc00152 inhibited the proliferation and clone formation of these three cancer cell lines (all P<0.05) (Fig. 8A and  8B ). Moreover, increased apoptosis was observed after the downregulation of linc00152 in the three cancer cell lines by flow cytometry (all P<0.05) (Fig. 8C) . Decreased migration and invasion were also observed in MDA-MB-231 cell line with knockdown of linc00152 (all P<0.05) (Fig. 8D) . Next, SGC-7901 cells transfected with either scramble or shRNAs were applied to examine linc00152 role in vivo. Tumor growth in the shRNAs group was slower than that in the scramble group (P< 0.001) (see online suppl. material, Fig. S3A &B) . Finally, RIP and RNA pull-down assays were applied to interpret the molecular mechanism of linc00152 in cancer. The results shown that endogenous linc00152 was enriched in the anti-EZH2 compared to the IgG in SGC-7901 cells (P< 0.01) (see online suppl. material, Fig. S3C ). Furthermore, RNA pull-down assays confirmed the interaction (see online suppl. material, Fig. S3D ). It was reported that EZH2 could bind to promoter of tumor suppressor genes and inhibited their expression [31] [32] [33] [34] [35] . Together, these results demonstrate linc00152 promotes cancer development via EZH2 directly.
Discussion
Linc00152, a 828-bp lncRNA that maps to chromosome 2p11.2, was initially defined as differentially hypomethylated during hepatocarcinogenesis [36] . In this study, the expression Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of linc00152 in pan-cancer was performed, and the relationship between linc00152 expression and prognosis, chemoresistance, genomic and epigenetic regulation, including DNA methylation and histone modification, was also investigated. Additionally, we elucidated the potential biological functions of linc00152 in tumorigenesis and progression using three types of cancer in vitro (MDA-MB-231, SGC-7901 and 786-O). All of the results indicated that linc00152 acted as an oncogenic propellant in pan-cancer from various perspectives. Previously published studies have revealed that the knockdown of linc00152 could inhibit cell proliferation and suppress cell cycle progression [22, 37, 38] . In our study, we obtained similar results to such studies. Moreover, the pathways downstream of linc00152 were not fully understood. Linc00152 was upregulated in hepatocellular carcinoma tissues and could induce cell proliferation in vitro and tumor growth in vivo by activating the mTOR signaling pathway [22] . The PI3K-Akt signaling pathway was discovered in our study via KEGG analysis. Moreover, linc00152 induces chemoresistance in pan-cancer via analysis of the public GEO datasets and published reports. Thus, linc00152 would be a bona fide oncogenic gene. Linc00152 may be associated with the regulation of the infection process which were annotated by GO and KEGG analyses, respectively (see online suppl. material, Table S2 ). Microbial infections may disrupt the physiological homeostasis; thus, linc00152 would favor tumorigenesis and cancer progression. Interestingly, linc00152 was closely related to the regulation of immunity annotated by GO and KEGG analyses, respectively (see online suppl. material, Table S2 ). Cancer immunotherapy is complicated in solid malignancies due to multiple factors, such as the patient's gut microbiome, their diet, and an underlying infection, which can affect or contribute to the success or failure of immune therapy. Yet, as complicated and incompletely understood is the immunology and the relationship between linc00152 expression and immune regulation observed in this study, targeting linc00152 would be an alternative strategy to improve the immunotherapy effect in solid cancer patients.
The mechanism of the upregulation of linc00152 in pan-cancer remains unclear. Transcription factor specificity protein 1 may induce its overexpression in gallbladder cancer [38] . Additionally, there is no other report regarding the exploration of such a mechanism. In this study, genomic and epigenetic regulation was applied to solve this issue. The results indicated that gene amplification was observed in almost all cancers, and low linc00152 locus methylation was observed in 17 types of cancer compared with their counterparts via analysis of Illumina Infinium HumanMethylation450 Beadchip in TCGA. Moreover, linc00152 is regarded as a promoter-like lncRNA via the analysis of H3K4me3/H3K4me1 enrichment in 15 cancer cell lines, and linc00152 was regulated by a super-enhancer. Genomic and epigenetic regulation of linc00152 explained the mechanism of its overexpression in pancancer. Moreover, other regulators such as transcription factors, microRNAs, RNA-binding protein and so on would be investigated in future work.
Overall, the comprehensive study of linc00152 in this work broadens the oncogenic lncRNA landscape of pan-cancer. This study revealed linc00152 as a potential therapy target and may aid in the comprehensive management of pan-cancer.
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